Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001237276 | SCV001410030 | pathogenic | Metachromatic leukodystrophy | 2024-12-09 | criteria provided, single submitter | clinical testing | This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 302 of the ARSA protein (p.Cys302Tyr). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of metachromatic leukodystrophy (PMID: 32632536; internal data). ClinVar contains an entry for this variant (Variation ID: 963270). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt ARSA protein function with a positive predictive value of 95%. This variant disrupts the p.Cys302 amino acid residue in ARSA. Other variant(s) that disrupt this residue have been observed in individuals with ARSA-related conditions (PMID: 33385934), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. |
Amsterdam Leukodystrophy Center, |
RCV001237276 | SCV001424852 | pathogenic | Metachromatic leukodystrophy | 2020-06-24 | criteria provided, single submitter | clinical testing | Homozygous - novel (late-infantile MLD) |